373 related articles for article (PubMed ID: 22045708)
1. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
2. Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal cancer xenograft model.
Vangestel C; Van de Wiele C; Mees G; Mertens K; Staelens S; Reutelingsperger C; Pauwels P; Van Damme N; Peeters M
Mol Imaging; 2012 Apr; 11(2):135-47. PubMed ID: 22469241
[TBL] [Abstract][Full Text] [Related]
3. Looking through the vascular normalization window: timing antiangiogenic treatment and chemotherapy with (99m)Tc-annexin A5.
Lewis MR
J Nucl Med; 2011 Nov; 52(11):1670-2. PubMed ID: 21994408
[No Abstract] [Full Text] [Related]
4. In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells.
Vangestel C; Peeters M; Oltenfreiter R; D'Asseler Y; Staelens S; Van Steenkiste M; Philippé J; Kusters D; Reutelingsperger C; Van Damme N; Van de Wiele C
Nucl Med Biol; 2010 Nov; 37(8):965-75. PubMed ID: 21055628
[TBL] [Abstract][Full Text] [Related]
5. Early Prediction of Tumor Response to Treatment: Preclinical Validation of 99mTc-Duramycin.
Elvas F; Vangestel C; Pak K; Vermeulen P; Gray B; Stroobants S; Staelens S; Wyffels L
J Nucl Med; 2016 May; 57(5):805-11. PubMed ID: 26837335
[TBL] [Abstract][Full Text] [Related]
6. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
7. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of adenosine preconditioning with 99mTc-His10-annexin V in a porcine model of myocardium ischemia and reperfusion injury: preliminary study.
Ye F; Fang W; Wang F; Hua ZC; Wang Z; Yang X
Nucl Med Biol; 2011 May; 38(4):567-74. PubMed ID: 21531294
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
10. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
11. Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-annexin V.
Mochizuki T; Kuge Y; Zhao S; Tsukamoto E; Hosokawa M; Strauss HW; Blankenberg FG; Tait JF; Tamaki N
J Nucl Med; 2003 Jan; 44(1):92-7. PubMed ID: 12515881
[TBL] [Abstract][Full Text] [Related]
12. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
13. Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-annexin V uptake and histologic findings in an experimental model.
Takei T; Kuge Y; Zhao S; Sato M; Strauss HW; Blankenberg FG; Tait JF; Tamaki N
J Nucl Med; 2004 Dec; 45(12):2083-7. PubMed ID: 15585485
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of radiation-induced tissue apoptosis by (99m)Tc(I)-his (6)-annexin A5.
Lin KJ; Wu CC; Pan YH; Chen FH; Fu SY; Chiang CS; Hong JH; Lo JM
Ann Nucl Med; 2012 Apr; 26(3):272-80. PubMed ID: 22278351
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.
Arjaans M; Oude Munnink TH; Oosting SF; Terwisscha van Scheltinga AG; Gietema JA; Garbacik ET; Timmer-Bosscha H; Lub-de Hooge MN; Schröder CP; de Vries EG
Cancer Res; 2013 Jun; 73(11):3347-55. PubMed ID: 23580572
[TBL] [Abstract][Full Text] [Related]
16. Time course of Paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer.
Erba PA; Manfredi C; Lazzeri E; Minichilli F; Pauwels EK; Sbrana A; Strauss HW; Mariani G
J Nucl Med; 2010 May; 51(5):775-81. PubMed ID: 20395330
[TBL] [Abstract][Full Text] [Related]
17. (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.
Belhocine TZ; Blankenberg FG; Kartachova MS; Stitt LW; Vanderheyden JL; Hoebers FJ; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2083-97. PubMed ID: 26275392
[TBL] [Abstract][Full Text] [Related]
18. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.
Heijmen L; Ter Voert EG; Punt CJ; Heerschap A; Oyen WJ; Bussink J; Sweep CG; Laverman P; Span PN; de Geus-Oei LF; Boerman OC; van Laarhoven HW
Contrast Media Mol Imaging; 2014; 9(3):237-45. PubMed ID: 24700751
[TBL] [Abstract][Full Text] [Related]
19. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation.
Takei T; Kuge Y; Zhao S; Sato M; Strauss HW; Blankenberg FG; Tait JF; Tamaki N
J Nucl Med; 2005 May; 46(5):794-9. PubMed ID: 15872353
[TBL] [Abstract][Full Text] [Related]
20. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
